Atea Pharmaceuticals, Inc. — All Filings
294 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
3
4
4/A
424B4
8-A12B
8-K
ARS
CERT
CORRESP
D
D/A
DEF 14A
DEFA14A
DFAN14A
DRS
DRS/A
DRSLTR
EFFECT
POS AM
POSASR
S-1
S-1/A
S-1MEF
S-3
S-3ASR
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13D
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 4 | FORM 4 SUBMISSION | 0000899243-23-003629 | Feb 2, 2023 | Jan 31, 2023 |
| 4 | FORM 4 SUBMISSION | 0000899243-23-003604 | Feb 2, 2023 | Jan 31, 2023 |
| 4 | FORM 4 SUBMISSION | 0000899243-23-003600 | Feb 2, 2023 | Jan 31, 2023 |
| 4 | FORM 4 SUBMISSION | 0000899243-23-003621 | Feb 2, 2023 | Jan 31, 2023 |
| 4 | FORM 4 SUBMISSION | 0000899243-23-003607 | Feb 2, 2023 | Jan 31, 2023 |
| SC 13G/A | — | 0001306550-23-003083 | Jan 24, 2023 | — |
| 4 | FORM 4 SUBMISSION | 0000899243-22-035942 | Nov 15, 2022 | Nov 11, 2022 |
| 8-K | 8-K | 0001193125-22-279097 | Nov 7, 2022 | — |
| 10-Q | 10-Q | 0000950170-22-022699 | Nov 7, 2022 | Sep 30, 2022 |
| 8-K | 8-K | 0001193125-22-214871 | Aug 8, 2022 | — |
| 10-Q | 10-Q | 0000950170-22-015570 | Aug 8, 2022 | Jun 30, 2022 |
| 4 | FORM 4 SUBMISSION | 0000899243-22-023505 | Jun 21, 2022 | Jun 17, 2022 |
| 4 | FORM 4 SUBMISSION | 0000899243-22-023502 | Jun 21, 2022 | Jun 17, 2022 |
| 4 | FORM 4 SUBMISSION | 0000899243-22-023501 | Jun 21, 2022 | Jun 17, 2022 |
| 4 | FORM 4 SUBMISSION | 0000899243-22-023498 | Jun 21, 2022 | Jun 17, 2022 |
| 4 | FORM 4 SUBMISSION | 0000899243-22-023496 | Jun 21, 2022 | Jun 17, 2022 |
| 8-K | 8-K | 0001193125-22-177774 | Jun 21, 2022 | Jun 17, 2022 |
| 4 | FORM 4 SUBMISSION | 0000899243-22-023504 | Jun 21, 2022 | Jun 17, 2022 |
| EFFECT | — | 9999999995-22-001427 | May 12, 2022 | — |
| 8-K | 8-K | 0001193125-22-145634 | May 10, 2022 | — |
| POS AM | POS AM | 0001193125-22-146286 | May 10, 2022 | — |
| 10-Q | 10-Q | 0000950170-22-008732 | May 10, 2022 | Mar 31, 2022 |
| DEFA14A | DEFA14A | 0001193125-22-134271 | Apr 29, 2022 | — |
| DEF 14A | DEF 14A | 0001193125-22-134263 | Apr 29, 2022 | Jun 17, 2022 |
| POS AM | POS AM | 0001193125-22-058650 | Mar 1, 2022 | — |
| POSASR | POSASR | 0001193125-22-058027 | Feb 28, 2022 | — |
| 10-K | 10-K | 0001564590-22-007672 | Feb 28, 2022 | Dec 31, 2021 |
| 8-K | 8-K | 0001193125-22-057911 | Feb 28, 2022 | — |
| SC 13G/A | SC 13G/A | 0001104659-22-024235 | Feb 16, 2022 | — |
| SC 13G/A | ATEA PHARMACEUTICALS, INC. | 0001104659-22-022762 | Feb 14, 2022 | — |
| SC 13G/A | — | 0000929638-22-000477 | Feb 14, 2022 | — |
| SC 13G/A | SC 13G/A | 0001193125-22-034452 | Feb 10, 2022 | — |
| SC 13G | SCHEDULE 13G | 0001104659-22-016552 | Feb 9, 2022 | — |
| SC 13G/A | — | 0000315066-22-000787 | Feb 9, 2022 | — |
| SC 13G | — | 0000834237-22-007341 | Feb 4, 2022 | — |
| 4 | FORM 4 SUBMISSION | 0000899243-22-004186 | Feb 2, 2022 | Jan 31, 2022 |
| 4 | FORM 4 SUBMISSION | 0000899243-22-004183 | Feb 2, 2022 | Jan 31, 2022 |
| 4 | FORM 4 SUBMISSION | 0000899243-22-004185 | Feb 2, 2022 | Jan 31, 2022 |
| 4 | FORM 4 SUBMISSION | 0000899243-22-004182 | Feb 2, 2022 | Jan 31, 2022 |
| 4 | FORM 4 SUBMISSION | 0000899243-22-004184 | Feb 2, 2022 | Jan 31, 2022 |
| 4 | FORM 4 SUBMISSION | 0000899243-22-004181 | Feb 2, 2022 | Jan 31, 2022 |
| 8-K | 8-K | 0001193125-22-005119 | Jan 10, 2022 | — |
| 4 | FORM 4 SUBMISSION | 0000899243-21-049313 | Dec 21, 2021 | Dec 20, 2021 |
| SC 13G | — | 0000935836-21-000685 | Dec 10, 2021 | — |
| 8-K | 8-K | 0001193125-21-341283 | Nov 26, 2021 | — |
| S-3ASR | S-3ASR | 0001193125-21-340320 | Nov 24, 2021 | — |
| 8-K | 8-K | 0001193125-21-331369 | Nov 16, 2021 | Nov 12, 2021 |
| 8-K | 8-K | 0001193125-21-327268 | Nov 12, 2021 | Nov 11, 2021 |
| 10-Q | 10-Q | 0001564590-21-056513 | Nov 12, 2021 | Sep 30, 2021 |
| SC 13D/A | SC 13D/A | 0001193125-21-282487 | Sep 24, 2021 | — |